1. Home
  2. DOCS vs ACAD Comparison

DOCS vs ACAD Comparison

Compare DOCS & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Doximity Inc.

DOCS

Doximity Inc.

HOLD

Current Price

$25.74

Market Cap

4.6B

Sector

Technology

ML Signal

HOLD

Logo ACADIA Pharmaceuticals Inc.

ACAD

ACADIA Pharmaceuticals Inc.

HOLD

Current Price

$22.41

Market Cap

3.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DOCS
ACAD
Founded
2010
1993
Country
United States
United States
Employees
N/A
N/A
Industry
Retail: Computer Software & Peripheral Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.6B
3.8B
IPO Year
2021
2000

Fundamental Metrics

Financial Performance
Metric
DOCS
ACAD
Price
$25.74
$22.41
Analyst Decision
Buy
Buy
Analyst Count
22
22
Target Price
$45.50
$30.55
AVG Volume (30 Days)
2.9M
1.5M
Earning Date
05-13-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
54.17
69.12
EPS
0.88
0.02
Revenue
$570,399,000.00
$726,437,000.00
Revenue This Year
$15.08
$18.80
Revenue Next Year
$8.83
$11.70
P/E Ratio
$29.65
$1,127.50
Revenue Growth
19.98
40.45
52 Week Low
$20.55
$19.69
52 Week High
$76.51
$28.35

Technical Indicators

Market Signals
Indicator
DOCS
ACAD
Relative Strength Index (RSI) 59.40 51.62
Support Level $23.30 $21.04
Resistance Level $27.09 $22.91
Average True Range (ATR) 0.93 0.73
MACD 0.28 0.03
Stochastic Oscillator 81.09 55.56

Price Performance

Historical Comparison
DOCS
ACAD

About DOCS Doximity Inc.

Doximity Inc is a digital platform for U.S. medical professionals. The cloud-based platform provides members with tools specifically built for medical professionals, enabling them to collaborate with their colleagues, securely coordinate patient care, conduct virtual patient visits, stay up-to-date with the latest medical news and research, and manage their careers and on-call schedules.

About ACAD ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.

Share on Social Networks: